Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss - Fierce Pharma
Fierce Pharma Asia—Merck-Kelun ADC’s triple wins; Tools in China licensing deals; Takeda’s $885M antitrust loss Fierce Pharma